Cynosure Group LLC Has $569,000 Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Cynosure Group LLC decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,630 shares of the company’s stock after selling 359 shares during the quarter. Cynosure Group LLC’s holdings in Krystal Biotech were worth $569,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Norges Bank acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $34,391,000. State Street Corp lifted its stake in Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after buying an additional 119,936 shares during the period. Raymond James Financial Inc. bought a new position in Krystal Biotech during the fourth quarter worth about $15,989,000. Franklin Resources Inc. grew its position in shares of Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after buying an additional 62,178 shares during the period. Finally, TimesSquare Capital Management LLC grew its position in shares of Krystal Biotech by 39.1% during the 4th quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock worth $24,888,000 after buying an additional 44,646 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Down 3.2 %

NASDAQ:KRYS opened at $174.58 on Wednesday. The firm has a market capitalization of $5.03 billion, a price-to-earnings ratio of 58.39 and a beta of 0.87. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The stock’s 50 day moving average price is $171.92 and its two-hundred day moving average price is $173.26.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the firm earned $0.30 earnings per share. The company’s revenue was up 116.4% on a year-over-year basis. Equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analyst Weigh In

KRYS has been the topic of several research analyst reports. Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. Chardan Capital lifted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Citigroup increased their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and an average price target of $220.00.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).